Physician profile
Max E Mercado
NPI 1336151182
$51,970.81
in general payments reported to CMS, 2019-2025
79 companies · $3,104 in 2025
The $3,104 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,612 · 2020: $6,274 · 2021: $13K · 2022: $4,568 · 2023: $13K · 2024: $5,236 · 2025: $3,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,364 · Travel and Lodging: $4,761 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,033.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,363.79 |
| Travel and Lodging | $4,760.71 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15,756.26 | 2019-2025 | |
| Allergan, INC. | $5,761.67 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $4,875.46 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $3,737.91 | 2019-2025 | Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $2,415.91 | 2019 | |
| Modernatx, INC. | $1,812.94 | 2023 | |
| Lilly USA, LLC | $1,783.70 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $1,705.50 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceuticals, INC. | $1,340.65 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,155.94 | 2019-2024 | Trulance, Xifaxan, Cycloset |
| Amgen INC. | $1,150.08 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $871.07 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $772.95 | 2019-2025 | Jardiance, Ofev |
| Sanofi-Aventis U.S. LLC | $573.88 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $572.48 | 2019-2022 |
Show all 77 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Mercado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.